Articles tagged with Fatty Liver Disease
A new study published in Nature Metabolism suggests that excessive fructose consumption can lead to a leaky gut and subsequently cause fatty liver disease. The researchers found that the high fructose corn syrup disrupts the epithelial barrier protecting internal organs from bacterial toxins, leading to chronic inflammatory conditions.
Researchers developed a new microscopy technique to visualize NAFLD progression in real-time, capturing details of lipid accumulation and immune cell behavior. The approach provides a highly useful research tool for identifying key parameters contributing to the disease.
A high-protein diet with a calorie-reduced intake was found to decrease liver fat by around 40% in obese individuals with non-alcoholic fatty liver disease. The study suggests that the positive effect of the high-protein diet is due to suppressed uptake, storage, and synthesis of fat in the liver.
A review article suggests postmenopausal women are at higher risk for developing nonalcoholic fatty liver disease (NAFLD) due to the decline in estrogen levels. Normal-weight women with normal lipid, glucose, and insulin levels are at low risk for NAFLD.
Researchers at UPV/EHU University of the Basque Country discover osteopontin's protective role in preventing early onset of metabolic fatty liver disease. Maintaining physiological levels of osteopontin is essential to delay disease progression during ageing.
Non-alcoholic fatty liver disease (NAFLD) affects both obese and non-obese individuals, with distinct differences found in male and female patients of varying body mass indexes. Key findings include lower skeletal muscle mass and insulin resistance in non-obese NAFLD patients compared to their obese counterparts.
A Wayne State University team has made significant breakthroughs in understanding the causal relationships between nonalcoholic fatty liver disease (NAFLD), type-2 diabetes, and obesity. They discovered two subtypes of NAFLD: one caused by genetic factors and another driven by metabolic syndrome.
Australian experts warn of a surge in chronic liver disease due to alcohol misuse and obesity-related liver disease. The number of cases has increased three-fold over the past 10-15 years, with over 6 million Australians affected.
Researchers have discovered a new target and therapy to fight NAFLD, a major health issue affecting 25% of the world population. Using siRNA to silence MCJ protein, they found reduced liver steatosis and fibrosis in preclinical mouse models.
A recent study reveals the cause behind the link between non-alcoholic fatty liver disease and neurological problems, including Alzheimer's disease-like symptoms. The unique role of an adipokine called Lipocalin-2 in causing neuroinflammation may explain the prevalence of MAFLD among individuals with neurological disorders.
A new study uses stool microbiomes to predict cirrhosis risk in patients with nonalcoholic fatty liver disease. Researchers found a unique signature that distinguishes cirrhosis from other causes of the disease, potentially leading to an accurate, non-invasive diagnostic tool.
A Phase II trial found that the treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression to non-alcoholic steatohepatitis. The study showed robust reduction in liver fat without corresponding increases in blood lipids.
Women with non-alcoholic fatty liver disease (NAFLD) in pregnancy face increased risks of maternal and infant health complications. The study found that NAFLD is associated with hypertensive complications, preterm birth, and maternal bleeding after delivery, independent of other metabolic diseases.
A new study found that fecal transplants can reduce intestinal permeability in patients with non-alcoholic fatty liver disease (NAFLD), a condition associated with metabolic syndrome and autoimmune diseases. The treatment shows promise for improving gut health and preventing further inflammation.
Researchers found an unexpected connection between electron imbalance in liver cells and many metabolic problems, including cardiovascular disease and fatty liver disease. The study identified a biomarker, alpha-hydroxybutyrate, to test for reductive stress and suggests LbNOX as a potential treatment.
Scientists from GIST developed a novel peripheral serotonin antagonist, which showed promising results in obese mice with impaired liver function. The compound improved symptoms of fatty liver disease and reduced body fat. Researchers hope the drug candidate will offer relief to patients with nonalcoholic fatty liver disease.
Recent studies on NAFLD have made significant progress in understanding the risk factors, diagnosis, and treatment of the condition. The latest research emphasizes the importance of gut microbiota modulation to improve severity, as well as the role of hepatic inflammatory pathways in driving comorbidities.
Researchers have identified three new genes that play a role in preventing fatty liver development. The genes IRGM, Ifgga2, and Ifgga4 produce regulatory proteins that counteract fat accumulation in the liver, but genetic variations lead to reduced protein production, resulting in increased fat content.
NAFLD affects 5.7% of adults in the US, progressing to cirrhosis in 39% over 8 years, with risk factors including cardiovascular disease and high cholesterol.
A new study led by Dr. Rohit Kohli shows that stevia extract can reduce markers of fatty liver disease, improving glucose levels and reducing cellular stress. The findings suggest potential benefits for pediatric patients with non-alcoholic fatty liver disease.
A study published at Digestive Disease Week found that nearly 83% of 9/11 first responders had fatty liver disease, compared to 24-45% in the general population. The research highlights the link between toxin exposure and non-alcoholic fatty liver disease among first responders.
Researchers from Joslin Diabetes Center have identified a potential early biomarker for non-alcoholic fatty liver disease (NAFLD), which is linked to the regulation of liver fat metabolism and fibrosis. The protein NREP was found to decrease in levels as NAFLD progressed, suggesting its role as an early indicator of the disease.
Researchers found that bariatric surgery significantly decreased liver enzymes, Fatty Liver Index, and BARD score in patients with NAFLD. Gastric bypass was associated with the greatest reduction in liver damage.
Researchers redefine Non-Alcoholic Fatty Liver Disease (NAFLD) as Metabolic Associated Fatty Liver Disease (MAFLD), a condition characterized by liver fat build-up affecting over 1 billion people. The new definition aims to improve treatment pathways, trial design, and drug development for this disease.
A ketogenic diet reduced liver fat content and improved insulin resistance in overweight participants. The diet also increased hydrolysis of triglycerides and promoted ketogenesis, suggesting a possible mechanism for reversing nonalcoholic fatty liver disease.
Yale scientists have discovered the molecular mechanisms that trigger metabolic imbalance between glucose production and energy utilization in the liver. They found that a protein called INSP3R1 regulates both gluconeogenesis and fat oxidation in response to glucagon, providing new insights into glucagon biology.
A novel cause of fatty liver disease has been discovered in lean individuals undergoing immune checkpoint blockade therapy. Researchers report a case of a woman who experienced severe inflammation of her subcutaneous fat and developed nonalcoholic fatty liver disease after treatment with the PD-1 inhibitor Nivolumab.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
Researchers found that green tea extract and exercise reduced fatty liver deposits by 75% in mice fed a high-fat diet, suggesting a potential health strategy for people. The study also showed increased gene expression related to energy metabolism in mice treated with both green tea extract and exercise.
Researchers have discovered that indole, a natural compound found in gut bacteria and cruciferous vegetables, can reduce inflammation and fatty deposits in the liver. This study provides hope for new treatments and preventive measures for non-alcoholic fatty liver disease (NAFLD).
Researchers developed a small molecule drug CTPI-2 that targets Slc25a1 gene involved in lipid and glucose metabolism, preventing liver damage, obesity and glucose intolerance in mice. The study showed promising results, confirming the importance of this gene in fatty liver disease.
A UK study found that over 20% of young adults have fatty liver disease, with those who are overweight or obese at greatest risk. The research highlights the need for improved liver health awareness and management among this age group.
SIRT6, a longevity protein, plays a crucial role in burning and regulating liver fat metabolism. By activating PPAR-alpha, it promotes fat burning and protects against fatty liver and obesity-related damage.
A new study found that people with non-alcoholic fatty liver disease have lower physical work capacity due to a functional iron deficiency, which impairs energy production. The research suggests focusing on improving iron availability through diet may be more effective than exercise in addressing the condition.
A new study published in Cancer Research found that excess fat in the liver impairs a tumor-suppressing protein named HNF4α, increasing cancer risk. The research provides potential mechanisms for the growing incidence of liver cancer linked to fatty liver disease.
A new therapy shows promise in reducing liver fat and fibrosis in people with HIV, a form of non-alcoholic fatty liver disease (NAFLD). The study found that tesamorelin reduced liver fat by 37% and slowed the progression of fibrosis in treated subjects.
Researchers found that tesamorelin reduced liver fat and prevented liver fibrosis in people living with HIV. The study showed a 37% relative reduction in liver fat fraction and a significant decrease in blood markers associated with inflammation and liver damage.
Researchers found a significant association between psoriasis and non-alcoholic fatty liver disease (NAFLD) severity, with higher psoriasis severity linked to more severe hepatic damage. The study suggests that patients with both conditions should be closely monitored and managed to prevent worsening of both diseases.
The prevalence of NAFLD is rising due to a preventable epidemic, with over half of adults and one third of children classified as overweight or obese. The condition is linked to lack of physical activity, excess calorie intake, and sugary drinks.
Researchers found that microcystin can significantly amplify non-alcoholic fatty liver disease even at low levels. The toxin was processed differently in the kidneys of mice with pre-existing liver disease, suggesting a need for special preventative guidelines.
Researchers discovered that a common type of gut bacteria, Klebsiella pneumoniae, produces high levels of alcohol in the body and can cause liver damage even in non-drinkers. The study found that 60% of patients with non-alcoholic fatty liver disease (NAFLD) had high- and medium-alcohol-producing K. pneumonia in their gut.
Researchers at Massachusetts General Hospital developed a lab-on-a-chip platform to study non-alcoholic fatty liver disease (NAFLD) progression. The platform allows for detailed studies of NAFLD's effects on liver cells and evaluates the potential of investigational drugs.
Researchers from The Westmead Institute for Medical Research have discovered how fatty liver disease develops in lean people. Lean patients tend to have worse outcomes due to an 'obesity-resistant' profile, despite having higher levels of bile acids and FGF19, which increase energy expenditure.
Researchers at the University of Pittsburgh School of Medicine have successfully grown genetically modified miniature human livers in a laboratory setting. These mini livers mimic non-alcoholic fatty liver disease progression and can be used to test therapeutics, providing a valuable tool for understanding and treating diseases.
Research from the University of Sydney found that electric fans lowered core temperature and cardiovascular strain in hot, humid conditions, but were detrimental in very hot, dry conditions. The study highlights the limitations of using heat index values to recommend fan use during heat waves.
Michelle Long, MD, MSc, assistant professor of medicine at Boston University School of Medicine, has been awarded a three-year, $495,000 Doris Duke Clinical Scientist Development Award to investigate the relationship between physical activity and NAFLD. The study aims to identify biomarkers of early disease and risk for progression.
A study by Clemson researchers found that the Cyp2b gene is associated with obesity and fatty liver disease in male mice, regardless of diet. The discovery suggests that enzymes involved in detoxification may play a role beyond diet and exercise in weight management and metabolic health.
A new blood test shows promise in replacing liver biopsies for children with Non-Alcoholic Fatty Liver Disease (NAFLD), a condition affecting one in 10 children. The test detects different types of fats in the blood, indicating inflammation and scarring.
Researchers at Cincinnati Children's Hospital Medical Center develop human liver organoids that accurately mimic key features of fatal liver diseases. The study reveals molecular secrets of deadly ailments and tests a potential therapy for Wolman disease, reversing an often-fatal childhood condition.
Researchers at Duke-NUS Medical School and NHCS found that deactivating IL11 with therapeutic antibodies reverses inflammation and scarring in patients with non-alcoholic steatohepatitis (NASH). This breakthrough has implications for the development of drugs to treat NASH, a common condition affecting millions worldwide.
A 30-day Ramadan fast has shown promising implications for timing and duration between meals, increasing proteins that play a crucial role in improving insulin resistance. The study suggests dawn-to-sunset fasting could provide a cost-effective intervention for those struggling with obesity-related conditions.
A study of 18 million people across Europe found that people with type 2 diabetes are at particular risk of non-alcoholic fatty liver disease (NAFLD) and its aggressive form NASH. The study suggests that targeted interventions and treatments can be effective in preventing life-threatening disease progression.
A recent study published in Clinical Gastroenterology and Hepatology found a significant association between glyphosate exposure and nonalcoholic fatty liver disease (NAFLD) in human subjects. The study, led by Paul J. Mills, PhD, examined urine samples from patients with NAFLD and healthy individuals, revealing higher levels of glypho...
Researchers found a connection between intrahepatic cholestasis of pregnancy and non-alcoholic fatty liver disease, suggesting impaired bile acid metabolism as a potential link. Women with ICP were 5.7 times more likely to have a diagnosis of fatty liver disease than controls.
A study examining national survey data found that approximately 10.9 million Americans have alcoholic fatty liver disease, highlighting the need for awareness and prevention efforts. The study's findings also suggest a significant association between heavy drinking and the development of this condition.
A team at IRB Barcelona has identified Mitofusin 2 as a protein that protects against non-alcoholic fatty liver disease. Early diagnosis and treatment options for this condition are limited, but researchers hope to enhance levels of Mitofusin 2 without side effects.
A study published in the journal Obesity found that nonhuman primates on a Mediterranean diet ate fewer calories, had lower body weight, and less body fat compared to those on a Western diet. The findings suggest that a Mediterranean diet may protect against obesity-related diseases.
A study of over 4,000 young adults in the UK found that nearly 20% had nonalcoholic fatty liver disease, and one in 40 had advanced fibrosis. The condition is linked to obesity, diabetes, and hyperlipidaemia, highlighting the need for greater public health awareness.
Two independent studies found high rates of liver disease progression and mortality among patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), highlighting the importance of early detection and treatment to prevent progression and reduce mortality. Advanced liver diseases progressed in up to 11% o...
A new molecule, EPB-53, has been discovered to increase FGF21 levels in the liver and plasma through oral administration. This could lead to new therapeutic strategies for treating type 2 diabetes and non-alcoholic fatty liver disease.